We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Boehringer Looking Into Possible Heart Failure Risk With Mirapex
FDA, Boehringer Looking Into Possible Heart Failure Risk With Mirapex
September 21, 2012
The FDA is working with Boehringer Ingelheim to look into a possible increased risk of heart failure with Mirapex, a Parkinson’s disease and restless leg syndrome drug.